MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

Search

BioMarin Pharmaceutical Inc

Atvērts

SektorsVeselības aprūpe

54.91 0.16

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.99

Max

55.18

Galvenie mērījumi

By Trading Economics

Ienākumi

241M

426M

Pārdošana

80M

825M

P/E

Sektora vidējais

15.935

35.739

EPS

1.44

Peļņas marža

51.637

Darbinieki

3,040

EBITDA

95M

319M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+77.7% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.2B

10B

Iepriekšējā atvēršanas cena

54.75

Iepriekšējā slēgšanas cena

54.91

Ziņu noskaņojums

By Acuity

20%

80%

42 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. okt. 16:58 UTC

Peļņas

BMW Trims 2025 View, Citing Weaker Performance in China

2025. g. 7. okt. 23:43 UTC

Tirgus saruna

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. g. 7. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. g. 7. okt. 23:19 UTC

Tirgus saruna

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. g. 7. okt. 22:40 UTC

Tirgus saruna

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. g. 7. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 20:44 UTC

Karstas akcijas

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. g. 7. okt. 19:42 UTC

Tirgus saruna

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. g. 7. okt. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. g. 7. okt. 19:07 UTC

Tirgus saruna

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. g. 7. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025. g. 7. okt. 15:33 UTC

Tirgus saruna

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025. g. 7. okt. 15:25 UTC

Tirgus saruna

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025. g. 7. okt. 15:15 UTC

Tirgus saruna

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025. g. 7. okt. 14:52 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

BioMarin Pharmaceutical Inc Prognoze

Cenas mērķis

By TipRanks

77.7% augšup

Prognoze 12 mēnešiem

Vidējais 97.2 USD  77.7%

Augstākais 122 USD

Zemākais 60 USD

Pamatojoties uz 22 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioMarin Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

22 ratings

18

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

59.405 / 62.19Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

42 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat